Literature DB >> 24309637

Drugs with dual-hormone action gain attention in diabetes field.

Veronica Hackethal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24309637     DOI： 10.1038/nm1213-1549

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  6 in total

1.  Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts.

Authors:  L N Axelsen; W Keung; H D Pedersen; E Meier; D Riber; A L Kjølbye; J S Petersen; S D Proctor; N-H Holstein-Rathlou; G D Lopaschuk
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.

Authors:  Brian Finan; Tao Ma; Nickki Ottaway; Timo D Müller; Kirk M Habegger; Kristy M Heppner; Henriette Kirchner; Jenna Holland; Jazzminn Hembree; Christine Raver; Sarah H Lockie; David L Smiley; Vasily Gelfanov; Bin Yang; Susanna Hofmann; Dennis Bruemmer; Daniel J Drucker; Paul T Pfluger; Diego Perez-Tilve; Jaswant Gidda; Louis Vignati; Lianshan Zhang; Jonathan B Hauptman; Michele Lau; Mathieu Brecheisen; Sabine Uhles; William Riboulet; Emmanuelle Hainaut; Elena Sebokova; Karin Conde-Knape; Anish Konkar; Richard D DiMarchi; Matthias H Tschöp
Journal:  Sci Transl Med       Date:  2013-10-30       Impact factor: 17.956

3.  Targeted estrogen delivery reverses the metabolic syndrome.

Authors:  Brian Finan; Bin Yang; Nickki Ottaway; Kerstin Stemmer; Timo D Müller; Chun-Xia Yi; Kirk Habegger; Sonja C Schriever; Cristina García-Cáceres; Dhiraj G Kabra; Jazzminn Hembree; Jenna Holland; Christine Raver; Randy J Seeley; Wolfgang Hans; Martin Irmler; Johannes Beckers; Martin Hrabě de Angelis; Joseph P Tiano; Franck Mauvais-Jarvis; Diego Perez-Tilve; Paul Pfluger; Lianshan Zhang; Vasily Gelfanov; Richard D DiMarchi; Matthias H Tschöp
Journal:  Nat Med       Date:  2012-11-11       Impact factor: 53.440

4.  A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.

Authors:  Victor A Gault; Vikas K Bhat; Nigel Irwin; Peter R Flatt
Journal:  J Biol Chem       Date:  2013-10-28       Impact factor: 5.157

5.  Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.

Authors:  Alessandro Pocai; Paul E Carrington; Jennifer R Adams; Michael Wright; George Eiermann; Lan Zhu; Xiaobing Du; Aleksandr Petrov; Michael E Lassman; Guoqiang Jiang; Franklin Liu; Corey Miller; Laurie M Tota; Gaochao Zhou; Xiaoping Zhang; Michael M Sountis; Alessia Santoprete; Elena Capito'; Gary G Chicchi; Nancy Thornberry; Elisabetta Bianchi; Antonello Pessi; Donald J Marsh; Ranabir SinhaRoy
Journal:  Diabetes       Date:  2009-07-14       Impact factor: 9.461

6.  Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia.

Authors:  Tricia M Tan; Benjamin C T Field; Katherine A McCullough; Rachel C Troke; Edward S Chambers; Victoria Salem; Juan Gonzalez Maffe; Kevin C R Baynes; Akila De Silva; Alexander Viardot; Ali Alsafi; Gary S Frost; Mohammad A Ghatei; Stephen R Bloom
Journal:  Diabetes       Date:  2012-12-17       Impact factor: 9.461
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.